The Benefit of Subcutaneous Glucagon During Closed-Loop Glycemic Control in Rats With Type 1 Diabetes

Because of its prolonged action, subcutaneously administered insulin has a potential for overcorrection hypoglycemia during closed-loop glucose control. For this reason, we hypothesized that subcutaneous glucagon, whose action is faster, could lessen the risk for hypoglycemia during closed-loop cont...

Full description

Saved in:
Bibliographic Details
Published in:IEEE sensors journal 2008-01, Vol.8 (1), p.89-96
Main Authors: Ward, W.K., Engle, J., Duman, H.M., Bergstrom, C.P., Kim, S.F., Federiuk, I.F.
Format: Article
Language:English
Subjects:
Algorithm
Algorithms
Animals
artificial pancreas
Automatic control
Biochemistry
Blood
closed-loop
Derivatives
Diabetes
Errors
Glucose
Hyperglycemia
Hypoglycemia
Insulin
Pancreas
Rats
Sugar
Temperature control
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Because of its prolonged action, subcutaneously administered insulin has a potential for overcorrection hypoglycemia during closed-loop glucose control. For this reason, we hypothesized that subcutaneous glucagon, whose action is faster, could lessen the risk for hypoglycemia during closed-loop control. We therefore compared insulin alone versus insulin plus glucagon in diabetic rats in a controlled closed-loop study. Both hormones were delivered by algorithms based on proportional error, derivative error, and the glucose history. Based on this algorithm, glucagon was delivered when glucose was declining and approaching a hypoglycemic level. The delivery of glucagon was largely reciprocal with the delivery of insulin. With the addition of glucagon, there was less hypoglycemia at the glucose nadir, less hyperglycemia later in the study, and lower absolute error values during these periods. We also found that for 7 days after glucagon reconstitution, commercially available glucagon retained its original ability to quickly raise glucose level. We conclude that when subcutaneous insulin delivery is accompanied by subcutaneous glucagon, glycemic control during closed-loop treatment is improved. Since its action is faster than that of insulin, glucagon may prove useful during closed-loop diabetes control.
ISSN:1530-437X
1558-1748
DOI:10.1109/JSEN.2007.912912